Neurologia

Estudos randomizados | Ublituximabe vs. teriflunomida na esclerose múltipla recorrente.

29 Ago, 2022 | 17:11h

Ublituximab versus Teriflunomide in Relapsing Multiple Sclerosis – New England Journal of Medicine (link para o resumo – $ para o texto completo)

 

Comentário no Twitter

In two parallel randomized trials in patients with MS, ublituximab resulted in lower relapse rates and fewer brain lesions on MRI than teriflunomide over a period of 96 weeks but did not affect disability. https://t.co/fpdtYhTNER pic.twitter.com/EPJEetSVdS

— NEJM (@NEJM) August 24, 2022

 

---

Comentário de estudo | Há evidências fortes para estimulação de medula espinal na neuropatia diabética? Nem todos os especialistas concordam.

29 Ago, 2022 | 16:56h

Is the Evidence Strong for Spinal Cord Stimulation for Diabetic Neuropathy? Not All Experts Agree – Neurology Today

Estudo original: RCT: Effect of High-frequency (10-kHz) Spinal Cord Stimulation in Patients With Painful Diabetic Neuropathy

 

---

Revisão sistemática | Carga anticolinérgica para predição de declínio cognitivo ou sintomas neuropsiquiátricos em idosos com comprometimento cognitivo leve ou demência.

29 Ago, 2022 | 16:33h

Anticholinergic burden for prediction of cognitive decline or neuropsychiatric symptoms in older adults with mild cognitive impairment or dementia – Cochrane Library

Resumo: The impact of cumulative medications with anticholinergic effects on future adverse clinical outcomes in people with dementia – Cochrane Library

Conteúdos relacionados:

Quantifying Anticholinergic Burden and Sedative Load in Older Adults with Polypharmacy: A Systematic Review of Risk Scales and Models – Drugs & Aging

Commonly-prescribed drugs and dementia: should we be worried? – Evidently Cochrane

Anticholinergic burden (prognostic factor) for prediction of dementia or cognitive decline in older adults with no known cognitive syndrome – Cochrane Library

Anticholinergic drugs and dementia: time for transparency in the face of uncertainty – Cochrane Library

Anticholinergic Drug Exposure and the Risk of Dementia: A Nested Case-Control Study – JAMA Internal Medicine

How well do you know your anticholinergic (antimuscarinic) drugs? – Therapeutics Initiative

Anticholinergic drugs and risk of dementia: case-control study – The BMJ

 

---

Estudo randomizado | Eficácia do ubrogepante no tratamento agudo da enxaqueca com dor leve vs. dor moderada ou grave.

29 Ago, 2022 | 15:48h

Efficacy of Ubrogepant in the Acute Treatment of Migraine With Mild Pain Versus Moderate or Severe Pain – Neurology

 

---

Estudo muito esperado sobre prevenção da doença de Alzheimer não encontra nenhum benefício clínico de medicamento direcionado a amiloide; aponta para a necessidade de considerar outras abordagens.

29 Ago, 2022 | 14:05h

Much Anticipated Alzheimer Disease Prevention Trial Finds No Clinical Benefit From Drug Targeting Amyloid; Highlights Need to Consider Other Approaches – JAMA (gratuito por tempo limitado)

 

Comentário no Twitter

The hypothesis that amyloid deposits in the brain cause Alzheimer disease has gotten many hits over the years, as one antiamyloid treatment after another failed to show a clinical benefit. Time to move on? @RitaRubin writes about the debate. https://t.co/913A0WWcR7

— JAMA (@JAMA_current) August 17, 2022

 

---

Um estudo de coorte de pacientes com lesão cerebral traumática leve mostrou que 56% dos pacientes tiveram recuperação incompleta após 6 meses.

29 Ago, 2022 | 14:03h

Outcomes in Patients With Mild Traumatic Brain Injury Without Acute Intracranial Traumatic Injury – JAMA Network Open

Comentário: Incomplete Recovery Common 6 Months After Mild TBI – Medscape (necessário cadastro gratuito)

Conteúdo relacionado: Cohort Study | Half of non-hospitalized patients with minor head injury experience incomplete recovery after 3 months.

 

Comentário no Twitter (fio – clique para saber mais)

1/🧵Mild Traumatic Brain Injury (TBI) isn’t “Mild” 🧠
 
Our daughter fell off a high diving board headfirst to cement years ago. Though she had 2 cracks through her foramen magnum, her GCS was 15 & CT had no bleeding.
 
“She’s OK,” they said.
 
Wrong answer 😔#TrackTBI Data… pic.twitter.com/1FZuRnt4so

— WesElyMD (@WesElyMD) August 22, 2022

 

---

Diretriz | Aplicação de medicações anticonvulsivantes no período perioperatório de cirurgia craniocerebral supratentorial.

29 Ago, 2022 | 13:56h

Chinese guideline on the application of anti-seizure medications in the perioperative period of supratentorial craniocerebral surgery – Therapeutic Advances in Neurologic Disorders

 

---

Análise observacional mostra que doença renal crônica está associada com risco aumentado de hemorragia intracerebral.

29 Ago, 2022 | 13:53h

Association of Chronic Kidney Disease With Risk of Intracerebral Hemorrhage – JAMA Neurology (link para o resumo – $ para o texto completo)

 

---

Revisão | Manipulação da temperatura: dispositivos para manejo da temperatura-alvo na lesão cerebral.

23 Ago, 2022 | 16:34h

Manipulating temperature: devices for targeted temperature management (TTM) in brain injury – Intensive Care Medicine (se o acesso a este link for pago, tente este)

 

---

Trajetórias de risco neurológico e psiquiátrico após infecção por SARS-CoV-2: análise de estudos de coorte retrospectiva de 2 anos incluindo 1.284.437 pacientes.

22 Ago, 2022 | 16:35h

Neurological and psychiatric risk trajectories after SARS-CoV-2 infection: an analysis of 2-year retrospective cohort studies including 1 284 437 patients – The Lancet Psychiatry

Comunicado de imprensa: Increased risk of some neurological and psychiatric disorders remains two years after COVID-19 infection – University of Oxford

Comentário: Covid-19: Increased risk of some neurological and psychiatric disorders remains two years after infection, study finds – The BMJ

 

Comentário no Twitter

NEW—People with #COVID19 continue to face increased risks of some neurological and psychiatric conditions up to 2 years after infection, according to a study published in @TheLancetPsych: https://t.co/9fD5zMU3hE pic.twitter.com/8YhTKJ9v72

— The Lancet (@TheLancet) August 17, 2022

 

---